Novo Nordisk files suits against 12 compounding defendants

Novo Nordisk has filed lawsuits against 12 more compounding pharmacies, telehealth companies, and med spas, expanding a legal campaign that had already reached more than 130 lawsuits across 40 states by mid-2025 ^[1]. The suits target businesses that make, market, or sell compounded versions of semaglutide, the active ingredient in Ozempic and Wegovy.

The legal push follows a key regulatory shift. In February 2025, the Food and Drug Administration declared that supplies of Ozempic and Wegovy now meet or exceed nationwide demand, removing semaglutide from the FDA's drug shortage list ^[1]. That declaration matters because federal compounding law generally bars pharmacies from making drugs that are "essentially a copy" of a commercially available FDA-approved product once a shortage ends ^[1]. Courts have since backed the FDA's position: the U.S. District Court for the Northern District of Texas denied attempts to reverse the shortage determination in April and June 2025 and dismissed the case with prejudice ^[1].

Under Sections 503A and 503B of the Food, Drug, and Cosmetic Act, a compounded drug counts as "essentially a copy" if it matches an FDA-approved product on four points: active ingredient, route of administration, dosage form, and strength ^[1]. For semaglutide, that means matching doses like 0.25mg, 0.5mg, 1mg, 1.7mg, or 2.4mg delivered by injection ^[1]. Compounders are allowed to fill a small number of prescriptions for such copies — the FDA has said it generally won't act against a pharmacy filling four or fewer prescriptions a month for the same compounded product — but volume beyond that threshold can trigger enforcement ^[1].

Novo Nordisk's suits rely on multiple legal theories, including trademark infringement, false advertising, unfair competition, and violations of federal drug laws covering misbranding and unapproved new drugs ^[1]. The company has already won permanent injunctions against a number of defendants, barring them from continuing to sell compounded semaglutide ^[1]. Eli Lilly, which makes tirzepatide-based Mounjaro and Zepbound, has filed similar suits against dozens of compounding pharmacies, clinics, and med spas ^[1].

The litigation is part of a broader enforcement push. Eighteen state pharmacy and medical boards have issued alerts to licensees about compounded GLP-1 products, and some states have gone further: Louisiana's Board of Pharmacy imposed restrictions on semaglutide compounding, and Alabama's State Board of Medical Examiners issued declaratory rulings on the practice ^[1]. State attorneys general in multiple states have issued consumer warnings as well ^[1].

Why it matters for patients

People using compounded semaglutide obtained from telehealth companies, med spas, or compounding pharmacies could see their supply disrupted if the business they rely on is named in a lawsuit, hit with an injunction, or shut down by a state board action ^[1]. Because compounded products are not FDA-approved, they have not gone through the agency's standard testing and approval process, which is part of why regulators and manufacturers argue they pose safety questions once brand-name supply is adequate ^[1].

Patients affected by these actions may need to talk with their prescriber about alternatives, since cost alone does not qualify as a "medical necessity" that would legally justify continued compounding once shortages are resolved ^[1]. It is not yet known from available sources how many patients are currently affected by the 12 new defendants named in this round of Novo Nordisk suits, or what timeline those specific cases will follow.

What happens next

Novo Nordisk's litigation campaign was continuing to expand as of the reporting period, with more than 130 total lawsuits filed across 40 states by mid-2025 ^[1]. The company has also pursued action against larger telehealth platforms, including a February 2026 legal filing against Hims & Hers seeking a permanent ban on sales of compounded versions of its drugs ^[1]. State licensing boards are also continuing investigations into individual prescribers and pharmacies tied to compounded GLP-1 sales ^[1]. Sources do not specify additional dates for resolution of the 12 newly named defendants' cases.